Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo

doi:10.1159/000368013

Shared by

Masatoshi Kudo

Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Article 2014 en

Authors

TA
Tadaaki Arizumi
KU
Kazuomi Ueshima
HC
Hirokazu Chishina

Abstract

1 min read

We conclude that decreased arterial enhancement during sorafenib treatment was associated with the longest OS and could therefore reflect an effective response.

Discussion(0)

No comments yet. Be the first to comment.

Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Abstract

Discussion(0)

Related publications

Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial.

Supplementary Material for: Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial

Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization

Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.

Related publications

Article2020
Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial.
Article2020

Dataset
Supplementary Material for: Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

Preprint2019
Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial
Preprint2019

Article2019
Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization
Article2019

Article2017
Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.
Article2017